2020 Guide to Patient Support Services

EMD Serono

EMD Serono and Pfizer provide the CoverOne program, a patient assistance program that offers reimbursement services, copay assistance, and billing and coding resources for patients who are prescribed Bavencio (avelumab), a fully human anti–PD-L1 monoclonal antibody.

Bavencio is indicated for the treatment of patients aged ≥12 years with metastatic Merkel-cell carcinoma, and for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy (Table).


CoverOne provides several support services for patients who are prescribed Bavencio. The program provides assistance options for patients with all types of insurance.

CoverOne Patient Assistance Program

Bavencio may be provided at no charge for uninsured patients who meet certain income and residency eligibility criteria.

CoverOne Co-Pay Assistance Program

Patients who enroll in the Cover­One Co-Pay Assistance program may be ­eligible for a $0 copay for each treatment for Bavencio, up to a maximum of $30,000 annually.

CoverOne Reimbursement Support Services

The reimbursement support services help patients and physicians understand the specific coverage and reimbursement guidelines for Bavencio, including insurance benefit verification; prior authorization assistance; information on the relevant billing codes; denied or underpaid claims assistance; payer research (not patient-specific) that covers Medicare, private payers, and state Medicaid; and alternate funding research.


CoverOne Patient Assistance Program

To determine eligibility, patients and their providers need to complete the patient enrollment form. Patients need to provide gross annual household income (before-tax wages), including Social Security benefits or any other source of household income, and supply income documentation.

After submission of the patient enrollment form and any required documents, a CoverOne representative will provide notification of the patient’s eligibility determination.

CoverOne Co-Pay Assistance Program

CoverOne can assist patients with private insurance copay or coinsurance responsibilities who meet the following program eligibility criteria:

  • Must not have any claims covered, paid, or reimbursed (in whole or part) by Medicaid, Medicare, or other federal or state healthcare programs
  • Eligible copay expenses must be connected with a separately paid claim for Bavencio administered in an outpatient setting, which is otherwise covered by a private or commercial plan.

Patients enrolled in this program may be eligible for a $0 copay for each treatment for Bavencio, up to a maximum of $30,000 annually.


To enroll in CoverOne programs and services, patients and their providers must complete the enrollment form. The form for single-agent use is available online. The form for avelumab in combination with axitinib is available online.

This form is required for reimbursement support, patient assistance support, and copay assistance support.


Patient support programs

Bavencio (avelumab) injection
Metastatic Merkel-cell carcinoma for patients aged ≥12 years; locally advanced or metastatic urothelial carcinoma that progressed with or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; first-line treatment of renal-cell carcinoma, in combination with axitinib
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: